ObvioHealth Launches API for DTx

ObvioHealth, a virtual research organization, has launched its proprietary application programming interface (API) specifically for digital therapeutic (DTx) clinical trials. The API provides DTx sponsors with a "plug and play" integration to ObvioHealth's ObvioGo® platform that addresses fundamental issues in DTx trial measurement.

"Adherence in a DTx trial isn't as simple as recording whether a participant took a pill or didn't. Instead, you need to capture the level of interaction between the participant and the DTx," said Craig Gravina, Chief Technology Officer at ObvioHealth. "This requires data to be captured directly from the source—the DTx itself—without prompts that might influence the participant's behavior."

ObvioHealth's API provides a tight integration between the digital therapeutic and the ObvioGo platform, providing data that correlates efficacy with adherence to the DTx.

ObvioHealth's mobile app can be used for complementary tasks, such as eConsent, screening, concomitant medication recording, televisits and the reporting of potential adverse events, in addition to other non-redundant eCOA data capture. The company is currently in the design phase for four DTx studies.

REFERENCE: ObvioHealth Announces Ground-Breaking Digital Therapeutics API to Capture More Accurate Efficacy and Adherence Data in Clinical Trials